ロード中...
RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40–70% survival. Secondary chemotherapy resistance contributes to treatment failure, where TP53 pathway dysfunction plays a key role. MDM2 interaction with TP53 leads to its degradation. Reactivating TP5...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5438615/ https://ncbi.nlm.nih.gov/pubmed/28427187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15840 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|